Stocks in London retreated on Friday, though ended the week as a whole higher, while gold notched a new record and sterling gained strength.The FTSE 100 index closed down 35.94 points, 0.4%, at 8,311.41. The FTSE 250 ended down 45.25 points, 0.2%, at 21,048.91, and the AIM All-Share closed down 0.52 of a point, 0.1%, at 774.27.For the week, the FTSE 100 ended 1.8% higher, the FTSE 250 gained 2.1%

Stock prices in London edged down at midday on Friday, although companies of all sizes in the gambling sector performed well.The FTSE 100 index was down 31.96 points, 0.4%, at 8,315.39. The FTSE 250 was down 27.94 points, 0.1%, at 21,066.22, and the AIM All-Share was down 1.92 points, 0.3%, at 772.87.The Cboe UK 100 was down 0.3% at 831.21, the Cboe UK 250 was down 0.1% at 18,451.52, and the Cboe

The FTSE 100 opened lower Friday morning despite a boost in retail sales in July, and underperforming against its counterparts in Paris and Frankfurt which traded higher.The FTSE 100 index opened just 3.93 points lower at 8,343.31. The FTSE 250 was down 14.52 points, or 0.1%, at 21,080.53, and the AIM All-Share was down 0.81 points, or 0.1%, at 773.98.The Cboe UK 100 was up 0.1% at 834.20, the Cbo

Stocks closed in the green in Europe on Thursday, as London's FTSE 100 extended its gains, while the UK economy had a 'remarkable rebound' in the second quarter.The FTSE 100 index closed up 66.30 points, 0.8%, at 8,347.35. The FTSE 250 ended up 141.87 points, 0.7%, at 21,094.16, and the AIM All-Share closed up 3.28 points, 0.4%, at 774.79.The Cboe UK 100 ended up 0.8% at 833.68, the Cboe UK 250 cl

There is a phrase in business ? 'shrink to greatness' ? meaning companies selling or demerging assets and focusing on what they do best.You might call it streamlining, others might say it is an admission that the previous strategy did not work and the company was too bloated.This trend is firmly in motion across the UK stock market with nine companies in the FTSE 100 either in the middle of shrink

Stocks in London took a hit on Friday, with New York also plummeting, after a slew of poor US economic data.The FTSE 100 index closed down 108.65 points, 1.3%, at 8,174.71. The FTSE 250 ended down 632.88 points, 3.0%, at 20,826.35, and the AIM All-Share closed down 11.81 points, 1.5%, at 771.27.Friday's fall meant London's blue-chip index ended a volatile week 1.3% worse off.The Cboe UK 100 ended

European stocks traded lower at midday on Friday as weak US data sparked concerns that growth in the world's largest economy could be slowing.The FTSE 100 index was down 34.90 points, 0.4%, at 8,248.46. The FTSE 250 was 358.17 points, 1.7%, at 21,101.06, and the AIM All-Share was down 5.27 points, 0.7%, at 777.81.The Cboe UK 100 was down 0.4%, the Cboe UK 250 was down 1.2% at 18,461.00, and the Cb

Q2 sales and earnings beat estimatesShares plunge on full-year downgradeRSV vaccine doses ship ahead of winterInvestors can be a tough bunch to please, just beating expectations is often not enough.Biotechnology firm Moderna (MRNA) is a case in point, with its shares slumping 21% overnight despite second quarter earnings coming in ahead of Wall Street estimates as the company slashed its full year

Stocks in Europe were in the green heading into Wednesday afternoon as markets digest a raft of earnings and await the US interest rate decision.The FTSE 100 index shot up 116.07 points, or 1.4%, at 8,390.48. But the FTSE 250 rose 135.79 points, 0.5%, at 21,568.30, while the AIM All-Share added 4.37 points, 0.6%, at 782.53.The Cboe UK 100 was up 1.2% at 837.75, the Cboe UK 250 added 0.5% to 18,892

Sales and earnings top expectationsDisappointing vaccine salesRaised full year outlookDespite delivering better-than-expected second-quarter sales and earnings growth and raising its full-year guidance, pharmaceutical giant GSK (GSK) saw its shares slip 2% to £15.19 as investors focused on disappointing vaccine sales.GSK has now delivered forecast-beating earnings in three of the last four quarte

Stocks in Europe traded higher on Wednesday morning amid a slew of corporate earnings and a rise in oil prices, after the Bank of Japan raised its main interest rate and before the Federal Reserve's decision later.The FTSE 100 index shot up 93.67 points, or 1.1%, at 8,368.08 on Wednesday morning. But the FTSE 250 rose 194.53 points, 0.9%, at 21,627.04, while the AIM All-Share added 3.72 points, 0.

The FTSE 100 closed in the red on Tuesday, underperforming against its European peers, as investors wait for three major interest rate decisions.The FTSE 250, however, got a boost. St James's Place took the spotlight, soaring 25%.The FTSE 100 index closed down 17.94 points, 0.2%, at 8,274.41. The FTSE 250 ended up 180.44 points, 0.9%, at 21,432.51, and the AIM All-Share closed up 0.84 of a point,

There has never been a better time to be an income investor in UK equities, as payouts for the period from April to June hit an all-time quarterly record of £36.7 billion according to the latest Dividend Monitor from Computershare.Most of the increase was thanks to one-off special dividends, leaving the underlying growth rate at just 1%, but for those clipping the coupons or reinvesting the incom

THIS IS AN ADVERTISING FEATURE Marketing material.A lot has been said about the concentration in the US markets, but investors in European markets have also been focused on a handful of companies. These 'Granolas' may be more diversified than the technology-focused Magnificent Seven ? and not as expensive ? but the focus on them suggests investors remain nervous about branching out. However, there

The FTSE 100 was in the green on Friday morning, while other stocks were mostly downbeat amid gloomy UK retail sales data and a global IT outage.Companies around the world reported technical issues, with planes grounded, trains disrupted, and television and radio broadcasters taken offline. According to Sky News, Berlin Airport has halted all flights until 0900 BST, while Microsoft Corp said it wa

US Centre for Disease Control restricts vaccine useDecision could limit vaccine salesGSK has a leading market share in RSV vaccinesShares in GSK (GSK) were marked down 5% to £15.16 after the US CDC (Centre for Disease Control) advised a narrower use of RSV (respiratory syncytial virus) vaccines, cutting the potential market for GSK's leading Arexvy vaccine.The drop eradicates most the year's gain

Stocks in London headed lower going into Thursday afternoon, with investors adopting a 'cautious' approach ahead of Friday's US inflation data.The FTSE 100 index traded 23.26 points lower, 0.3%, at 8,202.07. The FTSE 250 fell just 7.08 points at 20,291.02, while the AIM All-Share fell 3.08 points, 0.4%, at 762.84.The Cboe UK 100 fell 0.3% to 815.91, the Cboe UK 250 lost 0.1% at 17,654.85, and the

Equities in London made a slow start on Thursday, but peers in Europe traded more confidently, with market focus on upcoming US data and political developments either side of the English Channel, and across the Atlantic.In London, a US blow for GSK hurt its shares. Miners also struggled in early dealings. Elsewhere, there was a guidance boost for outsourcer Serco, Watches of Switzerland reported i

Covid-19 stock market darling Moderna (MRNA) appears to be getting its mojo back with investors following a punishing 85% drop in the shares from their September 2021 highs.Over the last six months Moderna's shares have more than doubled and despite the fall over the past couple of years, they remain one of the best performers in the benchmark S&P 500, notching up gains of 880% over the last five

Court ruling appeal process beginsGSK 'strongly' disagrees with prior rulingShares weighed down by litigation worriesGSK (GSK) confirmed it has taken steps to appeal a Delaware judge's decision (31 May) to allow 70,000 cases to go to trial and present expert testimony in ongoing litigation claims that its discontinued heartburn drug Zantac caused cancer.The company said it 'strongly' disagrees wit